Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Nanovesicle Drug Slips Through the Blood-brain Barrier to Selectively Target Brain Cancer Cells

By BiotechDaily International staff writers
Posted on 30 Jul 2013
Nanovesicles composed of the detergent saposin C-dioleoylphosphatidylserine (SapC-DOPS) that kill cancer cells by binding to phospholipid phosphatidylserine (PtdSer) residues exposed on the cells' surface membrane have the ability to cross the blood-brain barrier and destroy brain cancers such as glioblastoma multiforme (GBM).

GBM is an aggressive brain tumor, fatal within one year from diagnosis in most patients despite intensive treatment with surgery, radiation, and chemotherapy. The migratory and microscopically invasive nature of GBM as well as its resistance to chemotherapy renders conventional therapies inadequate in its treatment. Furthermore, brain cancer cells are protected by the blood-brain barrier, which prevents conventional drugs from reaching the tumor.

Investigators at Ohio State University (Columbus, USA) treated two different brain cancer-mouse models with the nanotech drug SapC-DOPS. They reported in the June 4, 2013, online edition of the journal Molecular Therapy that SapC-DOPS selectively and effectively crossed the blood-brain tumor barrier to target brain tumors in vivo and that the targeting was contingent on the exposure of the anionic phospholipid PtdSer on the surface of the cancer cells.

SapC-DOPS binding induced apoptosis in the tumor cells, and increased cell surface expression of PtdSer levels was found to correlate with SapC-DOPS-induced killing efficacy. Tumor targeting in vivo was inhibited by blocking PtdSer exposed on cells. In addition to its cancer cell killing ability, SapC-DOPS also exerted a strong antiangiogenic activity in vitro and in vivo.

“Few drugs have the capacity to cross the tumor blood-brain barrier and specifically target tumor cells,” said contributing author Dr. Balveen Kaur, associate professor of neurological surgery at Ohio State University. “Our preclinical study indicates that SapC-DOPS does both and inhibits the growth of new tumor blood vessels, suggesting that this agent could one day be an important treatment for glioblastoma and other solid tumors. Based on our findings, we speculate that SapC-DOPS could have a synergistic effect when combined with chemotherapy or radiation therapy, both of which are known to increase the levels of exposed PtdSer on cancer cells.”

Related Links:

Ohio State University




Channels

Genomics/Proteomics

view channel
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.